GlassScriptPhysician profile
Robert J Debruin
NPI 1073507786
$9,695.51
in general payments reported to CMS, 2019-2025
51 companies · $1,681 in 2025
The $1,681 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,589 · 2020: $1,148 · 2021: $1,406 · 2022: $1,208 · 2023: $1,355 · 2024: $1,307 · 2025: $1,681.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,324 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,324.36 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $998.32 | 2019-2025 | Ubrelvy, Vraylar, Linzess |
| Pfizer INC. | $835.91 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $608.72 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $561.73 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Madrigal Pharmaceuticals | $527.63 | 2024-2025 | Rezdiffra, Resmetirom |
| Merck Sharp & Dohme LLC | $477.44 | 2019-2024 | Gardasil 9, Dificid, Capvaxive |
| Lilly USA, LLC | $464.27 | 2020-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $454.85 | 2019-2025 | Evenity, Prolia, Repatha |
| Nestle Healthcare Nutrition INC. | $454.31 | 2021-2023 | |
| Novo Nordisk INC | $438.58 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Kowa Pharmaceuticals America, INC. | $403.15 | 2019-2023 | Livalo, Seglentis |
| Janssen Pharmaceuticals, INC | $352.84 | 2019-2025 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $294.30 | 2019-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $270.79 | 2019-2025 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $269.70 | 2021-2025 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Debruin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.